Log in

Relevant bibliographies by topics / Antiasthmatic agents / Journal articles

To see the other types of publications on this topic, follow the link: Antiasthmatic agents.

Journal articles on the topic 'Antiasthmatic agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 43 journal articles for your research on the topic 'Antiasthmatic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bianco, Sebastiano, Maria Grazia Pieroni, Rosa Metella Refini, Maria Robuschi, Adriano Vaghi, and Piersante Sestini. "Could NSAIDs Have a Role as Antiasthmatic Agents?" Drugs 48, no. 1 (July 1994): 9–15. http://dx.doi.org/10.2165/00003495-199448010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rajizadeh, Mohammad Amin, Hamid Najafipour, and Mohammad Abbas Bejeshk. "An Updated Comprehensive Review of Plants and Herbal Compounds with Antiasthmatic Effect." Evidence-Based Complementary and Alternative Medicine 2024 (February 8, 2024): 1–36. http://dx.doi.org/10.1155/2024/5373117.

Full text

Abstract:

Background. Asthma is a common disease with rising prevalence worldwide, especially in industrialized countries. Current asthma therapy with traditional medicines lacks satisfactory success, hence the patients’ search for alternative and complementary treatments for their diseases. Researchers have conducted many studies on plants with antiallergic and antiasthmatic effects in recent decades. Many of these plants are now used in clinics, and searching for their mechanism of action may result in creating new ideas for producing more effective drugs. Purpose. The goal of this review was to provide a compilation of the findings on plants and their active agents with experimentally confirmed antiasthmatic effects. Study Design and Method. A literature search was conducted from 1986 to November 2023 in Scopus, Springer Link, EMBASE, Science Direct, PubMed, Google Scholar, and Web of Science to identify and report the accumulated knowledge on herbs and their compounds that may be effective in asthma treatment. Results. The results revealed that 58 plants and 32 herbal extracted compounds had antiasthmatic activity. Also, 32 plants were shown to have anti-inflammatory and antioxidative effects or may act as bronchodilators and potentially have antiasthmatic effects, which must be investigated in future studies. Conclusion. The ability of herbal medicine to improve asthma symptoms has been confirmed by clinical and preclinical studies, and such compounds may be used as a source for developing new antiasthmatic drugs. Moreover, this review suggests that many bioactive compounds have therapeutic potential against asthma.

APA, Harvard, Vancouver, ISO, and other styles

3

Prasad, M. Raghu, R. H. Bahekar, and A. R. R. Rao. "ChemInform Abstract: Recent Perspectives in the Design of Antiasthmatic Agents." ChemInform 31, no. 41 (October 10, 2000): no. http://dx.doi.org/10.1002/chin.200041272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Khah, Shaila, Rohit Goyal, Ankush Chabba, Varun Jaiswal, Gaurav Sharma, and Mu Naushad. "Certain 4-Iminoflavones Derivatives: Synthesis, Docking Studies, Antiasthmatic and Antimicrobial Agents." Asian Journal of Chemistry 28, no. 8 (2016): 1687–96. http://dx.doi.org/10.14233/ajchem.2016.19789.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Anagnostopulos, Hiristo, Robert R. Bartlett, Ulrich Elben, and Paul Stoll. "Synthesis of basic substituted pyridines: a new class of antiasthmatic-antiallergic agents." European Journal of Medicinal Chemistry 24, no. 3 (May 1989): 227–32. http://dx.doi.org/10.1016/0223-5234(89)90003-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shringi, M., and C. Baregama. "1,3,7,8-SUBSTITUTED XANTHINE DERIVATIVES AS POTENTIAL ANTIASTHMATIC AGENTS WHICH ACT ON ADENOSINE RECEPTOR." INDIAN DRUGS 56, no. 07 (July 28, 2019): 84–87. http://dx.doi.org/10.53879/id.56.07.11436.

Full text

Abstract:

Asthma is one of the most common chronic diseases in modern society. There is a high prevalence of usage of complementary medicine for asthma. Xanthine derivatives which act on adenosine receptor have been cited as a most popular complementary treatment. This studys was undertaken to determine if there is any evidence for the clinical efficacy of xanthine derivatives for the treatment of asthma symptoms. This review highlights the more recent developments in the design and optimization of xanthine derivatives which act on A2A and A2B adenosine receptor. 1,3,8 and 1,3,7,8-substituted xanthine derivatives were found to be effetive. 1,3,7,8 Substituted xanthine derivative possess good affinity on A2A and A2B AR and are not selective for one particular receptor. This is benefitical for decreasing the side effects related to CVS.

APA, Harvard, Vancouver, ISO, and other styles

7

Gawali, U. P., and Anuradha deshkar. "PHARMACOVIGILANCE STUDY OF ANTIASTHMATIC AGENTS IN PATIENTS OF BRONCHIAL ASTHMA AT A TERTIARY CARE CENTRE." International Journal of Advanced Research 5, no. 3 (March 31, 2017): 1867–71. http://dx.doi.org/10.21474/ijar01/3703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bhosale, Uma, Shruti Jaiswal, Radha Yegnanarayan, and Gouri Godbole. "A pharmacovigilance study of antiasthmatic agents in patients of bronchial asthma at a tertiary care hospital." Journal of Clinical & Experimental Research 1, no. 2 (2013): 26. http://dx.doi.org/10.5455/jcer.201322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

YAMAGUCHI, Masahisa, Noriaki MARUYAMA, Takaki KOGA, Kenshi KAMEI, Michitaka AKIMA, Toshio KUROKI, Masatomo HAMANA, and Nobuhiro OHI. "Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. V. Thienopyridazinone Derivatives." CHEMICAL & PHARMACEUTICAL BULLETIN 43, no. 2 (1995): 236–40. http://dx.doi.org/10.1248/cpb.43.236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

YAMAGUCHI, Masahisa, Noriaki MARUYAMA, Takaki KOGA, Kenshi KAMEI, Michitaka AKIMA, Toshio KUROKI, Masatomo HAMANA, and Nobuhiro OHI. "Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. VI. Indazole Derivatives." CHEMICAL & PHARMACEUTICAL BULLETIN 43, no. 2 (1995): 332–34. http://dx.doi.org/10.1248/cpb.43.332.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Paramita, Swandari, Emil Bachtiar Moerad, Sjarif Ismail, and Eva Marliana. "Antiasthmatic effect of Curcuma aeruginosa extract on isolated organ of the trachea." F1000Research 7 (November 15, 2018): 1799. http://dx.doi.org/10.12688/f1000research.16416.1.

Full text

Abstract:

Background:Asthma is a major health problem worldwide. Antiasthma drugs have side effects and can be expensive. It is important to develop antiasthma drugs from medicinal plants that have fewer side effects and are cheaper. One of the medicinal plants used for antiasthma treatment comes fromCurcuma aeruginosa(Zingiberaceaefamily). The aim of the research is to examine spasmolytic activity of ethanol extract ofC. aeruginosaon isolated guinea pig tracheas to determine the antiasthma effects.Methods:The spasmolytic activity ofC. aeruginosaextracts was tested in separated organs of guinea pig trachea. Guinea pig was sacrificed and its trachea rings were suspended in L-shaped wire loops in organ baths containing the Krebs solution aerated with carbogen. Isometric contractions of tracheal rings were measured by the transducer coupled to the amplifier. The trachea rings were exposed to DMSO as negative control, aminophylline as positive control andC. aeruginosaextracts. The single concentration-relaxation curve was obtained in every preparation.Results:The result showed that the decrease of the spasmolytic activity in the guinea pig tracheal tone due toC. aeruginosaextract was significantly better (p=0.022) when compared to the negative control. Meanwhile, the EC50value of aminophylline (0.019 ± 0.05) was not significantly different (p=0.454) withC. aeruginosa(0.024 ± 0.05).Conclusion:It could be concluded thatC. aeruginosaextracts have the potency to be further developed as a new natural source of the antiasthma agents.

APA, Harvard, Vancouver, ISO, and other styles

12

Saeki, Sachiko, Hiroto Matsuse, Yuki Kondo, Ikuko Machida, Tetsuya Kawano, Shinya Tomari, Yasushi Obase, Chizu Fukushima, and Shigeru Kohno. "Effects of antiasthmatic agents on the functions of peripheral blood monocyte–derived dendritic cells from atopic patients." Journal of Allergy and Clinical Immunology 114, no. 3 (September 2004): 538–44. http://dx.doi.org/10.1016/j.jaci.2004.05.053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kore, Padmaja, Akash Gaikwad, Auradha G. More, Shivanjali Shinde, Rutuja Sawkar, and Poonam Inamdar. "Antihistaminic effects of Azadirachta indica leaves in laboratory animals." International Journal of Ayurvedic Medicine 13, no. 2 (July 8, 2022): 334–37. http://dx.doi.org/10.47552/ijam.v13i2.2559.

Full text

Abstract:

Azadirachta indica (Meliaceae) leaves have been traditionally used in the management of asthma and the current study was undertaken to scientifically validate the benefits of plant as an antihistaminic agent using the suitable animal model. The agents with antihistaminic properties are known to be good antiasthmatic agents; hence, in the current research work, the antihistaminic activity of an ethanolic extract of Azadirachta indica leaves (at a dose of 250 mg/kg, i.p.) was evaluated using haloperidol-induced catalepsy and clonidine-induced catalepsy in laboratory rats. The results showed that the ethanolic extract inhibits the catalepsy induced by the clonidine but no remarkable effect was observed on the catalepsy induced by haloperidol. This strongly suggests that, the inhibition is mediated through an antihistaminic action and there is no role of dopamine. Hence, in the present study, it is concluded that, the ethanolic extract has significant antihistaminic activity. The polar constituents in the ethanolic extract of leaves of Azadirachta indica may be responsible for the antihistaminic effects and therefore, the ethanolic leaves extract can be a better remedy as an antihistaminic agent.

APA, Harvard, Vancouver, ISO, and other styles

14

Singh, Navjeet. "A Review on Pharmacological Aspects of Achyranthes Aspera." International Journal of Pharmacognosy & Chinese Medicine 3, no. 4 (2019): 1–10. http://dx.doi.org/10.23880/ipcm-16000188.

Full text

Abstract:

Plant resources constitute an important natural wealth of Country. They play a significant role in providing primary health care service to rural people in addition large number of economic products. In contain secondary metabolites like alkaloids, glycosides, tannins, terpenoid, flavonoid, phenol, volatiles oils and many more compounds with serve as important therapeutic agents. Achyranthes aspera L(Amaranthaceae) is an important medicinal herb found as a weed throughout India. Achyranthes aspera is preninal herbbelonging to family Amaranthaceae. Wide numbers of phytochemical constituents have been isolated from the plant which possesses activities like antiperiodic, diuretic, purgative, laxative antiasthmatic, hepatoportective, anti-allergic and various other important medicinal properties. Traditionally, the plant is used in pneumonia, diarrhea, dysentery, asthma, cough, dropsy, ulcers, piles, rheumatism, scabies snake bite and other skin diseases. It contains the phytochemicals like oleanolic acid, Saponin A and saponin B.

APA, Harvard, Vancouver, ISO, and other styles

15

YAMAGUCHI, M., N. MARUYAMA, T. KOGA, K. KAMEI, M. AKIMA, T. KUROKI, M. HAMANA, and N. OHI. "ChemInform Abstract: Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. Part 6. Indazole Derivatives." ChemInform 26, no. 35 (August 17, 2010): no. http://dx.doi.org/10.1002/chin.199535169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

YAMAGUCHI, M., N. MARUYAMA, T. KOGA, K. KAMEI, M. AKIMA, T. KUROKI, M. HAMANA, and N. OHI. "ChemInform Abstract: Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. Part 5. Thienopyridazinone Derivatives." ChemInform 26, no. 35 (August 17, 2010): no. http://dx.doi.org/10.1002/chin.199535186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Zhang, Ming-Qiang, and Mariel E. Zwaagstra. "Structural Requirements for Leukotriene CysLT1 Receptor Ligands." Current Medicinal Chemistry 4, no. 4 (August 1997): 229–46. http://dx.doi.org/10.2174/0929867304666220313113236.

Full text

Abstract:

Leukotriene CysLT1 receptor antagonists (also known as LfD4 antagonists) are among the most promising antiasthmatic agents currently under investigation. For the last 20 years there are many thousands of compounds prepared as CysLT1 receptor antagonists and several of them have advanced to the clinical practice. The diverse chemical structures of CysLT1 antagonists pose considerable difficulty in the identification of structural determinants for their activity. This review summarizes the structural modifications within each individual class of compounds and derives the general structural requirements for CysLT1 antagonistic activity. Computer-aided rational design of CysL T1 antagonists have been thoroughly analyzed and a new pharmacophoric model is presented to accommodate almost all SAR data experimentally observed. Since a stable and selective CysLT1 receptor agonist would be a very useful pharmacological tool, especially for the characterization of receptor subtypes, the SARs of CysLT1 agonists have also been discussed in the present paper. These information are also important for the understanding of ligand recognition of the CysLT1 receptor.

APA, Harvard, Vancouver, ISO, and other styles

18

Kim, Seung-Hyung, Bok-Kyu Kim, and Young-Cheol Lee. "Antiasthmatic Effects of Hesperidin, a Potential Th2 Cytokine Antagonist, in a Mouse Model of Allergic Asthma." Mediators of Inflammation 2011 (2011): 1–12. http://dx.doi.org/10.1155/2011/485402.

Full text

Abstract:

Background and Objective. The features of asthma are airway inflammation, reversible airflow obstruction, and an increased sensitivity to bronchoconstricting agents, termed airway hyperresponsiveness (AHR), excess production of Th2 cytokines, and eosinophil accumulation in the lungs. To investigate the antiasthmatic potential of hesperidin as well as the underlying mechanism involved, we studied the inhibitory effect and anti-inflammatory effect of hesperidin (HPN) on the production of Th2 cytokines, eotaxin, IL-17, -OVA-specific IgEin vivoasthma model mice.Methods. In this paper, BALB/c mice were systemically sensitized to ovalbumin (OVA) followed intratracheally, intraperitoneally, and by aerosol allergen challenges. We investigated the effect of HPN on airway hyperresponsiveness, pulmonary eosinophilic infiltration, various immune cell phenotypes, Th2 cytokine production and OVA-specific IgE production in a mouse model of asthma.Results. In BALB/c mice, we found that HPN-treated groups had suppressed eosinophil infiltration, allergic airway inflammation, and AHR, and these occurred by suppressing the production of IL-5, IL-17, and OVA-specific IgE.Conclusions. Our data suggest that the therapeutic mechanism by which HPN effectively treats asthma is based on reductions of Th2 cytokines (IL-5), eotaxin, OVA-specific IgE production, and eosinophil infiltration via inhibition of GATA-3 transcription factor.

APA, Harvard, Vancouver, ISO, and other styles

19

Ashton, Michael J., David C. Cook, Garry Fenton, Jan-Anders Karlsson, Malcolm N. Palfreyman, David Raeburn, Andrew J. Ratcliffe, John E. Souness, Suga Thurairatnam, and Nigel Vicker. "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogs." Journal of Medicinal Chemistry 37, no. 11 (May 1994): 1696–703. http://dx.doi.org/10.1021/jm00037a021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Yamaguchi, Masahisa, Kenshi Kamei, Takaki Koga, Michitaka Akima, Akinori Maruyama, Toshio Kuroki, and Nobuhiro Ohi. "Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones." Journal of Medicinal Chemistry 36, no. 25 (December 1993): 4061–68. http://dx.doi.org/10.1021/jm00077a009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hameed, Huma, Arwa Khalid, Fazala Khalid, Rabeea Khan, and Akhtar Rasul. "Chrono pharmacotherapy: A pulsatile Drug Delivery." Pakistan Journal of Pharmaceutical Research 1, no. 1 (January 1, 2015): 25. http://dx.doi.org/10.22200/pjpr.2015125-32.

Full text

Abstract:

Chronopharmacotherapy refers to a treatment in which controlled drug delivery is achieved according to circadian rhythms of disease by enhancing therapeutic outcomes and minimizing side effects. Colon targeting has gained great importance not only for the treatment of local diseases such as Crohn’s disease, inflammatory bowel disease and ulcerative colitis but also very important in systemic delivery of proteins/peptides, antiasthmatic drugs, antidiabetic agents and antihypertensive drugs, which mostly show their efficacy based on circadian rhythms of the body.Colon drug delivery is one of the difficult approaches to achieve the targeted and desired outcomes through pulsatile drug delivery by avoiding dose dumping.The main reasonbehind the use of pulsatile delivery is provision ofconstant drug release where a zero-order release is notpreferred. Chronopharmacotherapy in colon targeting play its role bymany systems such ascapsular systems, pulsatile system and osmotic systems, which are based on use of rupturable membranes and biodegradable polymers.The objective of this review article is to provide latest knowledge about drugs with chrono-pharmacological behavior entails night time dosing specially to the colon.

APA, Harvard, Vancouver, ISO, and other styles

22

Ukita, Tatsuzo, Masakatsu Sugahara, Yoshihiro Terakawa, Tooru Kuroda, Kazuteru Wada, Aya Nakata, Yasushi Ohmachi, Hideo Kikkawa, Katsuo Ikezawa, and Kazuaki Naito. "Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridylnaphthalene Derivatives." Journal of Medicinal Chemistry 42, no. 6 (March 1999): 1088–99. http://dx.doi.org/10.1021/jm980314l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Jasim, Shaimaa Fakhri, Noor Nihad Baqer, and Esam Abd Alraheem. "DETECTION OF PHYTOCHEMICAL CONSTITUENT IN FLOWERS OF VIOLA ODORATA BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY." Asian Journal of Pharmaceutical and Clinical Research 11, no. 5 (May 1, 2018): 262. http://dx.doi.org/10.22159/ajpcr.2018.v11i5.24288.

Full text

Abstract:

Objective: Viola odorata has a characteristic as antifungal, antibacterial, anticancer, antioxidant, antiasthmatic, anti-inflammatory, anti-HIV, and antipyretic agents. The aim of this study was detected about bioactive compounds in the methanolic extract of V. odorata. Methods: The methanolic extract was analyzed through gas chromatography-mass spectrometry (GC-MS) for the identification of different compounds.Results: The current study investigated about phytochemicals in flowers of V. odorata. GC-MS analysis of the methanol extract of flowers showed 84 compounds. The highest concentration was for components which include ethanol, 2-(9,12-octadecadienyl oxy) -, (Z,Z)-; pentadecanoic acid; 1-pentacosanol; 1-pentacosanol; 2-furan carboxaldehyde, 5-(hydroxymethyl)-; 1,2 benzenedicarboxylic acid, diisooctyl ester; and docosane, 11-butyl- and gamma-sitosterol. The peak area and retention time for each components, respectively, were (15.709, 25.51%), (14.015, 19.51%), (29.914, 4.69%), (27.292, 3.95%), (5.707, 4.05%), (20.357, 3.91%), (18.289, 2.48%), and (30.431, 2.37%). While the others components ranged the peak area from 2.03% to 0.05%.Conclusions: These results indicate that the flowers of V. odorata contain the numerous components which have medical importance and this study was one of the first studies to detect phytochemicals in V. odorata.

APA, Harvard, Vancouver, ISO, and other styles

24

Yamaguchi, Masahisa, Kenshi Kamei, Takaki Koga, Michitaka Akima, Toshio Kuroki, and Nobuhiro Ohi. "Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones." Journal of Medicinal Chemistry 36, no. 25 (December 1993): 4052–60. http://dx.doi.org/10.1021/jm00077a008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

ASHTON, M. J., D. C. COOK, G. FENTON, J. A. KARLSSON, M. N. PALFREYMAN, D. RAEBURN, A. J. RATCLIFFE, J. E. SOUNESS, S. THURAIRATNAM, and N. VICKER. "ChemInform Abstract: Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4- methoxybenzamides and Analogues." ChemInform 25, no. 43 (August 18, 2010): no. http://dx.doi.org/10.1002/chin.199443106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Iwasaki, Tameo, Kazuhiko Kondo, Tooru Kuroda, Yasunori Moritani, Shinsuke Yamagata, Masaki Sugiura, Hideo Kikkawa, Osamu Kaminuma, and Katsuo Ikezawa. "Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis(hydroxymethyl)naphthalene Lignans." Journal of Medicinal Chemistry 39, no. 14 (January 1996): 2696–704. http://dx.doi.org/10.1021/jm9509096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

YAMAGUCHI, M., K. KAMEI, T. KOGA, M. AKIMA, A. MARUYAMA, T. KUROKI, and N. OHI. "ChemInform Abstract: Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. Part 2. 4-(3-Pyridyl)-1(2H)- phthalazinones." ChemInform 25, no. 25 (August 19, 2010): no. http://dx.doi.org/10.1002/chin.199425148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bashir, Fawad, Areej Komal, Ahsan Ibrahim, Qura Tul Ain, Bisma Rehman, and Tahreem Zaheer. "Exploring Nature's Invigorating Power: Phytotherapy for SARS-CoV-2." Phytopharmacological Communications 3, no. 1 (June 30, 2023): 39–51. http://dx.doi.org/10.55627/ppc.003.01.0292.

Full text

Abstract:

Covid-19 is a respiratory disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that spreads by person-to-person contact. The virus is thought to have a zoonotic origin. It mainly affects the respiratory system, resulting in fever, cough, shortness of breath, headaches, diarrhea, throat infections, and myalgia. It takes over the host's cell via the angiotensin-converting enzyme-2 receptors (ACE2). Despite the development of multiple vaccinations via diverse techniques, there is no scientifically significant therapy to combat SARS-CoV-2 infection. However, research into current therapeutic strategies' potential safety and effectiveness is in progress. This review briefly discusses the epidemiology of SARS-CoV-2, its pathophysiology, and the challenges of current treatment for SARS-CoV-2. The significance the medicinal plants and their extracts are discussed at length. Available literature suggests that aloe vera, senna, black cumin, and fenugreek have the potential to be effective antivirals against SARS-CoV-2. Many of these plants also have immunomodulatory, antiasthmatic, antipyretic, anti-tussive, and antiviral effects. Bioactive compounds such as quercetin, curcumin, epigallocatechin gallate, baicalin, andrographis, glycyrrhizin, and resveratrol have also been shown to relieve Covid-19 symptoms. We suggest that these medicinal plants may serve as a source of phytocompounds with safer and more potent antiviral agents against SARS-CoV-2 and should be investigated further in detail.

APA, Harvard, Vancouver, ISO, and other styles

29

YAMAGUCHI, Masahisa, Takaki KOGA, Kenshi KAMEI, Michitaka AKIMA, Noriaki MARUYAMA, Toshio KUROKI, Masatomo HAMANA, and Nobuhiro OHI. "Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. IV. 2-(2-(1-Imidazolyl)ethyl)-4-(3-pyridyl)-1(2H)-phthalazinones." CHEMICAL & PHARMACEUTICAL BULLETIN 42, no. 9 (1994): 1850–53. http://dx.doi.org/10.1248/cpb.42.1850.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

IWASAKI, T., K. KONDO, T. KURODA, Y. MORITANI, S. YAMAGATA, M. SUGIURA, H. KIKKAWA, O. KAMINUMA, and K. IKEZAWA. "ChemInform Abstract: Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis(hydroxymethyl) naphthalene Lignans." ChemInform 27, no. 43 (August 4, 2010): no. http://dx.doi.org/10.1002/chin.199643070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

YAMAGUCHI, M., K. KAMEI, T. KOGA, M. AKIMA, T. KUROKI, and N. OHI. "ChemInform Abstract: Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. Part 1. 2-(2-(1-Imidazolyl) alkyl)-1(2H)-phthalazinones." ChemInform 25, no. 25 (August 19, 2010): no. http://dx.doi.org/10.1002/chin.199425147.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kelly, H. William. "Comparison of Inhaled Corticosteroids." Annals of Pharmacotherapy 32, no. 2 (February 1998): 220–32. http://dx.doi.org/10.1345/aph.17014.

Full text

Abstract:

OBJECTIVE: To review the comparative studies evaluating both efficacy and safety of inhaled corticosteroids in the management of asthma. Specifically, comparative clinical trials are evaluated that allow clinicians to determine relative potencies of the various inhaled corticosteroids. METHODS: A critical review was performed of the published clinical trials, either as articles or abstracts, comparing the clinical efficacy or systemic activity of inhaled corticosteroids. No a priori criteria were applied, as this was not a meta-analysis. FINDINGS: In vitro measures of antiinflammatory activity of corticosteroids consistently demonstrate potency differences among the various corticosteroids. Traditionally, these in vitro measures have been used to develop new corticosteroids with greater topical activity. While no accepted direct measure of antiasthmatic antiinflammatory activity exists, clinical trials using surrogate measures (e.g., forced expiratory volume in 1 second, peak expiratory flow, bronchial hyperresponsiveness, symptom control) indicate that in vitro measures provide a relatively accurate assessment of antiasthmatic potency. The relative antiinflammatory potency of the inhaled corticosteroids is in the following rank order: flunisolide = triamcinolone acetonide < beclomethasone dipropionate = budesonide < fluticasone. Studies of systemic activity appear to confirm this relative order of potency. Currently, no evidence exists for greater efficacy for any of the inhaled corticosteroids when administered in their relative equipotent dosages. The preponderance of current data suggests that when administered in equipotent antiinflammatory doses as a metered-dose inhaler plus spacer or as their respective dry-powder inhaler, the existing inhaled corticosteroids have similar risks of producing systemic effects. CONCLUSIONS: Delivery systems can significantly affect both topical and systemic activity of inhaled corticosteroids. More direct comparative studies between agents are required to firmly establish comparative topical to systemic activity ratios. The preponderance of evidence suggests that the agents are not equipotent on a microgram basis. OBJETIVO: Resumir estudios comparativos que evalúen la efectividad y seguridad de corticosteroides por la vía de inhalación en el tratamiento de asma. Además, se evalúan estudios comparativos que puedan permitirle al profesional clínico determinar la potencia relativa de varios corticosteroides inhalados. MÉTODO: Evaluar críticamente los estudios clínicos publicados, ya sea en artículos o extractos que comparan efectividad clínica o actividad sistémica de corticosteroides inhalados. No se utilizaron criterios de inclusión para los artículos. RESULTADOS: Las medidas in vitro de actividad antiinflamatoria de los corticosteroides demostraron diferencias en potencia entre los diferentes agentes. Tradicionalmente, estas medidas in vitro se han utilizado para desarrollar nuevos corticosteroides con mayor actividad tópica. Aunque no existe una medida directa aceptada de la actividad antiinflamatoria, los estudios clínicos que usaban medidas (p.ej., el volumen expiratorio en 1 sec, el flujo expiratorio más alto, control de síntomas) indican que lo medido in vitro provee una evaluación bastante precisa de su potencia antiasmática. La potencia antiinflamatoria relativa de los corticosteroides inhalados tiene el siguiente orden: flunisolide = acetonide de triamcinolona < dipropionato de beclometasona = budenoside < fluticasone. Los estudios de actividad sistémica parecen confirmar este orden en potencia relativa. Actualmente no existe evidencia que demuestre diferencia en efectividad al administrar dosis equipotentes de los corticosteroides inhalados. La información disponible sugiere que el administrar dosis equipotentes a través de un inhalador de dosis premedida con un espaciador o el inhalador de dosis en polvo tiene un riesgo similar de producir efectos sistémicos. CONCLUSIONES: Los sistemas de liberación pueden afectar significativamente la actividad tanto tópica como sistémica de los corticosteroides inhalados. Se necesitan estudios comparativos para determinar la razón de actividad tópica a sistémica. La evidencia que predomina hasta el presente sugiere que los diferentes agentes no son equipotentes microgramo a microgramo. OBJECTIF: Revoir les études comparatives qui évaluent l'efficacité et la sûreté des corticostéroïdes à voie inspiratoire dans le traitement de l'asthme. Spécifiquement, on évalue les études cliniques comparatives qui permettent au clinicien de déterminer l'efficacité relative des corticostéroïdes à voie inspiratoire. MÉTHODES: Une revue analytique d'études cliniques publiées soit comme articles ou comme abstraits comparant refficacité clinique ou l'activité systémique des corticostéroïdes à voie inspiratoire. Aucun critère a priori a été utilisé parce que ce n'était pas une meta-analyse. RESULTATS: Les mesures d'activité anti-inflammatoire in vivo des corticostéroïdes démontrent de manière consistente qu'il existe des différences d'efficacité entre les corticostéroïdes variés. Traditionellement, lon emploie ces méthodes in vitro afin de développer de nouveaux corticostéroïdes avec une meilleure activité topique. Malgré qu'il n'existe pas une mesure directe d'activité anti-inflammatoire anti-asthmatique qui soit acceptée, les études cliniques qui utilisent des mesures indirectes (ex., volume expiratoire maximum 1 sec, le débit expiratoire de pointe, la hyperréactivité bronchique, le contrôle des symptômes) indiquent que les mesures in vitro donnent une évaluation relativement exacte d'efficacité anti-asthmatique. L'efficacité anti-inflammatoire relative des corticostéroïdes à voie inspiratoire suit cet ordre: le flunisonide = l'acétonide de triamcinolone < le dipropionate de beclaméthasone = le budésonide < le fluticasone. Les études d'activité systémique semble confirmer cet ordre d'efficacité relative. Présentement, il n'existe pas d'évidence qu'il ait une supériorité d'efficacité pour aucun des corticostéroïdes à voie inspiratoire lorsqu'administrés dans leur posologies equipotentes. La prépondérance des données suggère que lorsqu'ils sont administrés dans des doses anti-inflammatoire équipotentes avec un aérosoldoseur pressurisé avec une chambre d'inhalation “spacer” ou avec leur “DPI” respectif les corticostéroïdes à voie inspiratoire qui existent ont un risque semblable de produire des effets secondaires systémiques. CONCLUSIONS: Les systèmes de livraison peuvent affecter et l'activité topique et systémique des corticostéroïdes à voie inspiratoire. Des études comparatives plus directes entre les agents sont nécessaires afin d'établir plus définitivement le rapport relatif entre l'activité topique et systémique. La prépondérance de l'évidence suggère que ces agents ne sont pas équipotents milligramme pour milligramme.

APA, Harvard, Vancouver, ISO, and other styles

33

YAMAGUCHI, Masahisa, Takaki KOGA, Kenshi KAMEI, Michitaka AKIMA, Toshio KUROKI, Masatomo HAMANA, and Nobuhiro OHI. "Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. III. 4-(2-(5-Ethyl-2-thienyl))-2'-(2-(1-imidazolyl)ethyl)-1(2H)-phthalazinones." CHEMICAL & PHARMACEUTICAL BULLETIN 42, no. 8 (1994): 1601–4. http://dx.doi.org/10.1248/cpb.42.1601.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

YAMAGUCHI, M., T. KOGA, K. KAMEI, M. AKIMA, N. MARUYAMA, T. KUROKI, M. HAMANA, and N. OHI. "ChemInform Abstract: Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. Part 4. 2-(2-(1-Imidazolyl) ethyl)-4-(3-pyridyl)-1(2H)-phthalazinones." ChemInform 26, no. 18 (August 18, 2010): no. http://dx.doi.org/10.1002/chin.199518169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

YAMAGUCHI, M., T. KOGA, K. KAMEI, M. AKIMA, T. KUROKI, M. HAMANA, and N. OHI. "ChemInform Abstract: Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. Part 3. 4-(2-(5-Ethyl-2- thienyl))-2-(2-(1-imidazolyl)ethyl)-1(2H)-phthalazinones." ChemInform 26, no. 13 (August 18, 2010): no. http://dx.doi.org/10.1002/chin.199513201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lin, Shuai, Qianwen Sheng, Xiaobin Ma, Shanli Li, Peng Xu, Cong Dai, Meng Wang, Huafeng Kang, and Zhijun Dai. "Marsdenia tenacissima Extract Induces Autophagy and Apoptosis of Hepatocellular Cells via MIF/mToR Signaling." Evidence-Based Complementary and Alternative Medicine 2022 (March 4, 2022): 1–10. http://dx.doi.org/10.1155/2022/7354700.

Full text

Abstract:

Hepatocellular carcinoma (HCC) seriously endangers humans. In traditional Chinese medicine, Marsdenia tenacissima (MTE) has anti-inflammatory, antiasthmatic, antihypertensive, and anticancer effects. This study reveals the antiproliferative effect of MTE on the HCC cells in vitro and provides a theoretical basis for the development and clinical application of anti-HCC agents. Methods. MHCC-97H and HepG2 cells were cultured in vitro and exposed to various concentrations and durations of MTE, and an MTT assay was used to detect the effects of MTE on cell proliferation. Transmission electron microscopy revealed the morphological changes in the two cell lines after MTE stimulation. The MTE effects on the apoptosis and cell cycle distribution of the cell lines were detected by flow cytometry. Western blotting and qRT-PCR were used to detect target gene expression at the protein and mRNA levels, respectively. Results. MTE reduced the viability of the MHCC-97H and HepG2 cells in a dose- and time-dependent manners ( P < 0.05 ). Autophagic vesicles and apoptotic bodies were found in the MHCC-97H and HepG2 cells after MTE incubation, and the Annexin V-PI assay showed that the apoptotic rates of the cell lines increased with increasing MTE concentration ( P < 0.05 ). Autophagy inducer rapamycin promoted the MTE-induced apoptotic rates of the cell lines, whereas autophagy inhibitor chloroquine inhibited the apoptotic rates. More cells in the S phase were found in the two cell lines after MTE treatment ( P < 0.05 ). After MTE incubation, MIF, CD47, and beclin-1 protein levels significantly increased. Furthermore, in the MTE group, Akt, mTOR, and caspase3 expressions decreased; however, LC 3 expression increased, which was significantly different from the control group ( P < 0.05 ). Conclusions. MTE inhibited proliferation and induced autophagy, apoptosis, and S phase cell cycle arrest in the MHCC-97H and HepG2 cells. These effects might be related to the activation of MIF and mTOR signaling inhibition.

APA, Harvard, Vancouver, ISO, and other styles

37

"Screening methods for antiasthmatic agents." Methods and Findings in Experimental and Clinical Pharmacology 22, no. 3 (2000): 191. http://dx.doi.org/10.1358/mf.2000.22.3.796124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"The prescribing of antiasthmatic agents in Hong Kong is suboptimal." InPharma 704, no. 1 (September 1989): 4. http://dx.doi.org/10.1007/bf03319225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Schulze, Johannes. "Bronchial Allergen Challenges in Asthma Research." EMJ Respiratory, October 1, 2013, 87–91. http://dx.doi.org/10.33590/emjrespir/10312696.

Full text

Abstract:

In the development of new antiallergic or antiasthmatic therapies, mouse models have helped to identify novel therapeutic agents. Before a medication is evaluated for potency in phase II and phase III studies in humans, different bronchial challenge models are used to test the efficacy and mode of action in small sample sizes. Most published trials follow a classical approach in which allergic subjects are challenged with the same amount of allergen before and after treatment with a specific agent. Repeated challenge models are designed either to imitate natural allergen exposure or to induce significant asthma symptoms and airway inflammation. Although the available literature is less abundant, repeated models promise insights into the action of agents and the mechanisms of airway inflammation.

APA, Harvard, Vancouver, ISO, and other styles

40

ANAGNOSTOPULOS, H., R. R. BARTLETT, U. ELBEN, and P. STOLL. "ChemInform Abstract: Synthesis of Basic Substituted Pyridines: A New Class of Antiasthmatic-Antiallergic Agents." ChemInform 20, no. 41 (October 10, 1989). http://dx.doi.org/10.1002/chin.198941337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Okwuofu, Emmanuel Oshiogwe, Audrey Yong Chee Hui, Jonathan Lim Chee Woei, and Johnson Stanslas. "Molecular and Immunomodulatory Actions of New Antiasthmatic Agents: Exploring the Diversity of Biologics in Th2 Endotype Asthma." Pharmacological Research, May 2022, 106280. http://dx.doi.org/10.1016/j.phrs.2022.106280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Aboul Naser, Asmaa F., Amal M. El-Feky, and Manal A. Hamed. "Mitigating Effect of Lepidium sativum Seeds Oil on Ovarian Oxidative Stress, DNA Abnormality and Hormonal Disturbances Induced by Acrylamide in Rats." Chemistry & Biodiversity, May 14, 2024. http://dx.doi.org/10.1002/cbdv.202400062.

Full text

Abstract:

Acrylamide (ACR), an industrial compound, causes both male and female reproductive toxicity. Lepidium sativum seeds (L. sativum) (Garden cress) are known for their health benefits as antioxidant, antiasthmatic, anticoagulant, anti‐inflammatory, and analgesic agents. Therefore, this study aimed to investigate the phytochemistry and nutritional value of L. sativum seeds oil for attenuating the ovarian damage induced by acrylamide in rats. The phytochemical investigation of the seeds revealed the presence of vitamins, potassium, iron, sugar and amino acids. Twenty eight compounds from the unsaponifiable fraction and twenty three compounds from the saponifiable fraction were identified. Three sterols and two triterpenes were isolated and identified as β‐sitosterol (1), ∆5‐avenasterol (2), friedelanol (3), stigmasta‐4, 22‐dien‐3‐one (4), and ursolic acid (5). Treatment of acrylamide‐induced rats with L. sativum seeds oil ameliorated prolactin (PRL), progesterone (P4), estradiol (E2), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), nitric oxide (NO), interleukin‐6 (IL‐6), and tumor necrosis factor alpha (TNF‐ α) with variable degrees. The histopathological findings of ovaries supported these results. In conclusion, compounds (3‐5) were isolated for the first time from L. sativum seeds oil. The seeds oil attenuated the ovarian damage and could potentially be a new supplemental agent against female infertility.

APA, Harvard, Vancouver, ISO, and other styles

43

Fan, Maoxia, Kaibin Niu, Xiaoqi Wu, and Hongshuo Shi. "Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database." Frontiers in Pharmacology 15 (July 16, 2024). http://dx.doi.org/10.3389/fphar.2024.1417596.

Full text

Abstract:

ObjectiveThe purpose of this study is to explore and analyze the FDA Adverse Event Reporting System (FAERS) database to identify drug adverse reaction signals associated with angioedema. The findings aim to provide valuable insights for clinical drug safety considerations.MethodsThe Open Vigil 2.1 data platform was utilized to collect adverse event reports related to angioedema from the first quarter of 2004 to the fourth quarter of 2023. The reporting odds ratio (ROR) and proportional reporting ratio (PRR) were employed as disproportionality measures to detect adverse reaction signals Sof drugs associated with angioedema.ResultsA total of 38,921 reports were retrieved, with the majority being reported by healthcare professionals. The analysis included predominantly adult patients (≥18 years of age), with slightly higher representation of females compared to males. Among the top 30 drugs associated with the occurrence of angioedema, 24 drugs showed positive signals in the risk analysis. Based on the individual drug reporting odds ratio (95% confidence interval) as a measure of risk signal strength, the top five drugs are as follows: lisinopril [ROR (95% CI): 46.43 (42.59–50.62)], enalapril [ROR (95% CI): 43.51 (39.88–47.46)], perindopril [ROR (95% CI): 31.17 (27.5–35.32)], alteplase [ROR (95% CI): 29.3 (26.95–31.85)], ramipril [ROR (95% CI): 20.93 (19.66–22.28)]. After categorizing the drugs, the strongest positive signal was observed in the antithrombotic agents [ROR (95% CI): 22.53 (21.16–23.99)], following that, cardiovascular drugs [ROR (95% CI): 9.17 (8.87–9.48)], antibiotics [ROR (95% CI): 6.42 (5.91–6.96)], immunosuppressors [ROR (95% CI): 5.95 (5.55–6.39)], anti-inflammatory analgesics [ROR (95% CI): 4.65 (4.45–4.86)], antiallergic drugs [ROR (95% CI): 4.47 (3.99–5)], antiasthmatics [ROR (95% CI): 2.49 (2.14–2.89)], blood sugar control drugs [ROR (95% CI): 1.65 (1.38–1.97)], and digestive system drugs [ROR (95% CI): 1.59 (1.45–1.74)] exhibited progressively decreasing ROR values.ConclusionMany medications are associated with a high risk of angioedema. These medications play a crucial and potentially preventable role in controlling the occurrence of angioedema. It is essential to consider the risk level of drug-induced angioedema in clinical practice to optimize medication therapy.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!